
|Articles|September 7, 2007
Glaucoma laser treatment ready to go to trial
Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.
Advertisement
Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.
The second-generation OT134 system is based on the company's smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already undergone successful testing on 23 patients in clinical trials. The OT134 upgrades have been designed to offer improved efficacy and ergonomics.
IOPtima plans to initiate a multinational, long-term, human clinical trial later this year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















